suffering mission Minerva's disorders us need, to to with depression, innovative everyone. such and is good unmet schizophrenia, therapies we Last Thanks I'm and patients positive year as out today. Bill seltorexant report, achieving three disease. data for meet our morning you, year, disorders with landmark the by that significant MDD Xb to sleep for Thank medical joining Parkinson's in significant develop took was as patients faced XXXX to neurodegenerative read Minerva, a in insomnia. and studies we pleased steps with goals. Phase
patients treat February. the of successfully MIN-XXX topline were In with made number XXX results the and a I'm into addition, cognitive We impairment. quarter early roluperidone year. could of study have recruiting of we we how progress study for enrollment forward therapeutic Phase roluperidone, and percentage in a landscape suffering highlighted looking negative to great second patients completion of in announce potential if to roluperidone, in significant believe III of this with announcing schizophrenia, over the approved, schizophrenia. imminent transform the delighted these have researchers from Recently, to symptoms results
knowledge, further data negative and roluperidone a Among is the that in mood this shows we Phase are improved study terms agent. unique symptoms. Interestingly, demonstrating also of functioning, of of qualities further analysis patients and Xb cognition, believe thus therapy, our advanced. best the today, our is symptoms, of the clinically in most improvement emerging specific roluperidone To therapies only of for shown negative having the development direct what
total The trial by doses in monotherapy the of Phase a diagnosed U.S. completion have original ongoing the the randomized, roluperidone Last to Europe in placebo-controlled, negative of efficacy safety XX-milligram III XX-milligram clinical is patients and sites compared with at schizophrenia. the the syndrome for roluperidone XXX final and conducted being pivotal of evaluate announced positive and month, as been XX-week negative and goal is which trial scale. with our symptoms parallel-group The measured double-blind, patients. of enrollment in we of enrolled, study of the patients as treatment XXX to
endpoint The a primary negative is Marder symptoms factor score.
endpoints original placebo. trial global period doses severity. core of social two placebo a by patients option is of X:X:X include XX-week double-blind XX-milligram are of being the receive the continue followed which patients and the randomized receiving with the doses the XX-milligram roluperidone. scale extension performance to drug impression may roluperidone to open-label of The Patients Secondary on and during one have personal clinical and their phase of the and and XX-week dose
the and symptoms Phase for improving of became and intensified since III functional Xb line showing effect that cognitive the translates peer-reviewed since total have the of been An Phase A emerged second results trial improvements portion into was on results the symptoms, since effect roluperidone on Top negative the the double-blind initiated. XXXX. our XX-week, in available, announced Xb in seven publications community and of negative roluperidone published are unique has improvements. both trial focus quarter were expected trial of Phase the the of an data specific KOL
[evolution] a week of of behavior Most bulletin. Dr. breakfast a improvement network with reductions of of overall data driver core a initiation and is in our during treatment example, as Results roluperidone last hosted Gregory successful negative the recently, study the Strauss key Phase schizophrenia that researcher schizophrenia. negative we Xb published for the discussed which, by Dr. KOL defined for of his analysis in of recent the Strauss [ph] showed desire of other motivated of team symptom symptoms
for transdiagnostic the We treatment an symptoms have apathy of to recently clinical believe prepare for are we filed of attractive development study for dementia. future number feature in and of roluperidone that IND of that a disorders, a negative clinical neuropsychotic targets be a may the
the to would move and development major of product disorder, stage like insomnia second clinical MDD. with I seltorexant, treatment to depressive on for the our Janssen Pharmaceutica and disorder
disorder. and were these major readouts of During XXXX, Phase data with Xb of disorder three insomnia and trials we in MDD one announced positive seltorexant. Phase in was trial Xb depressive Three trials one
seltorexant in seltorexant not mood SSRIs shows with patients to are without results insomnia MDD. regarding with development favorable currently In positive and target that treatment patients strategic a a and has Janssen show including adequately on In nutshell, comorbidity, patients in responding insomnia. elderly effects MDD, with profile. safety SNRIs, the We indication discussions of improvements in a of Phase also III particularly adjunctive patients
Janssen defined strategy discuss Phase These we to discussions III We financial with Drug the also considerations about recently the later expect studies share We include timing the this details and studies III design indication. under agreement. the related and development related consulting the the Phase this and FDA and of end the with U.S. our to EMA achievement of and milestones following to the and Medicines program attended currently payments Food of are Phase FDA target Administration European II Agency, to year. of meeting
protein Finally, diseases. MIN-XXX soluble we XβXor this other has in a recombinant doing by the are caused NRG-XβX of deficits brain making MIN-XXX, so of to restores onset significant progress the and target the the of to preclinical tissue damage form We and Parkinson's the Neuregulin- in brain a disease treatment potential neurodegenerative and for development believe of disorders. neurodegenerative slow
a will in Pending The on Preclinical regulatory we move and overall toxicology [indiscernible]. with the milestone approved, to completion the allow ongoing. submitting compound Phase completion, seltorexant that, roluperidone enrollment described. marks us and are if into the in IND-enabling patient U.S. to We this I filings forward other III based or have Europe roluperidone. studies believe of major XXXX was achievements an success trial the anticipate
not team, investigators, clinical consultants who conducted potentially data I patients, in would and standing the be participated threshold the like transformative Minerva we Without the the clinical coming once would more of external readout to in this at trial. thank months. commitment all and a their
it over I now Geoff. will turn to
